APOE and atherosclerosis: Previous studies with atorvastatin (10 mg/kg/day) (16, 23, 31), alirocumab (10 mg/kg/week) (17), and evinacumab (25 mg/kg/week) (18) as mono-treatment in APOE*3-Leiden.CETP mice in an atherosclerosis prevention or progression mode showed reductions in plasma cholesterol (−53% to −71, −46, and −52%, respectively) and TGs (NS, −39%, and −84%), and strong reduction in development of atherosclerosis (−87, −88, and −39%, respectively).